The not-for-profit Global Alliance for TB Drug Development will bring its tuberculosis candidate pretomanid before the Antimicrobial Drugs Advisory Committee on 6 June seemingly without any major concerns from US Food and Drug Administration reviewers, who look to be exhibiting a degree of regulatory flexibility.
TB Alliance is developing pretomanid, a nitroimidazooxazine antimycobacterial drug, specifically as part of an oral combination regimen with Janssen...





